Welireg 40 mg, film-coated tablets

( ARTG ) von Hippel-Lindau (VHL) disease associated tumours,WELIREG (belzutifan) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.,Advanced Renal Cell Carcinoma (RCC),WELIREG (belzutifan) is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed cell death 1/ligand 1 (PD-1/L1) and a vascular endothelial growth factor (VEGF)-targeted therapy.